Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease...

Area of Science:

• Neuroscience
• Pharmacology
• Herbal Medicine

Background:

• Parkinson's disease (PD) involves neurodegeneration and motor deficits linked to catecholamine imbalance and oxidative stress.
• Withania somnifera (Ws), or Ashwagandha, is a traditional Indian herb with documented effects on neural growth and function.
• The specific impact of Ws on the biochemical and physiological markers of PD remains unclear.

Purpose of the Study:

• To investigate the effects of Ws on catecholamine levels and physiological abnormalities in a mouse model of Parkinson's disease.

Main Methods:

• Parkinson's disease was induced in mice using MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
• MPTP-induced PD mice were treated with Ws (100mg/kg) for 7 or 28 days.
• Levels of catecholamines (dopamine, DOPAC, HVA), antioxidants (GSH, GPx), and lipid peroxidation (TBARS) were measured in the striatum. Motor function was assessed using hang and rotarod tests.

Main Results:

• MPTP treatment reduced dopamine, its metabolites, and antioxidants, while increasing lipid peroxidation and causing motor deficits.
• Ws treatment normalized TBARS levels and increased dopamine, DOPAC, and HVA in the striatum.
• Ws administration improved motor function, with significant benefits observed after 7 days and enhanced antioxidant levels after 28 days.

Conclusions:

• Withania somnifera root extract demonstrates potential as a therapeutic agent for Parkinson's disease.
• Ws effectively addresses catecholamine depletion, oxidative damage, and motor impairments characteristic of PD.
• Further research into Ws as a PD treatment is warranted based on these findings.